what is bronchitis

Info about bronchitis coughing => bronchitis cures => Topic started by: glennaguilar on August 11, 2016, 02:53:17 am


Title: Are Bronchial Infections Contagious and Fluoroquinolone
Post by: glennaguilar on August 11, 2016, 02:53:17 am
Are Bronchial Infections Contagious - Fluoroquinolone Antibiotics Classification, Uses and Side Effects
Quote
The fluoroquinolones are a relatively new group of antibiotics. Fluoroquinolones were first introduced in 1986, but they are really modified quinolones, a class of antibiotics, whose accidental discovery occurred in the early 1960.

Gastrointestinal Effects
The most common adverse events experienced with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in 1 to 5% of patients.  CNS effects. Headache, dizziness, and drowsiness have been reported with all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, have been reported in patients receiving trovafloxacin. Seizures may develop within 3 to 4 days of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones should be avoided in patients with a history of convulsion, cerebral trauma, or anoxia. No seizures have been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. With the older non-fluorinated quinolones neurotoxic symptoms such as dizziness occurred in about 50% of the patients.  Phototoxicity. Exposure to ultraviolet A rays from direct or indirect sunlight should be avoided during treatment and several days (5 days with sparfloxacin) after the use of the drug. The degree of phototoxic potential of fluoroquinolones is as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin. Musculoskeletal effects. Concern about the development of musculoskeletal effects, evident in animal studies, has led to the contraindication of fluoroquinolones for routine use in children and in women who are pregnant or lactating.  Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within one week of discontinuation of therapy, spontaneous ruptures have been reported as long as nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant use of corticosteroids. Hepatoxicity. Trovafloxacin use has been associated with rare liver damage, which prompted the withdrawal of the oral preparations from the U.S. market. However, the IV preparation is still available for treatment of infections so serious that the benefits outweigh the risks. Cardiovascular effects. The newer quinolones have been found to produce additional toxicities to the heart that were not found with the older compounds. Evidence suggests that sparfloxacin and grepafloxacin may have the most cardiotoxic potential. Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia have been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia has been reported with other fluoroquinolones (levofloxacin and moxifloxacin), the effects have been mild. Hypersensitivity. Hypersensitivity reactions occur only occasionally during quinolone therapy and are generally mild to moderate in severity, and usually resolve after treatment is stopped. You actually learn more about Bronchitis only with more reading on matters pertaining to it. So the more articles you read like this, the more you learn about Bronchitis.

Fluoroquinolones are approved for use only in people older than 18. They can affect the growth of bones, teeth, and cartilage in a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating that these drugs have the potential to cause teratogenic or embryocidal effects. Giving fluoroquinolones during pregnancy is not recommended unless the benefits justify the potential risks to the fetus. These agents are also excreted in breast milk and should be avoided during breast-feeding if at all possible. :)

Conditions Treated With Fluoroquinolones: Indications and Uses
The newer fluoroquinolones have a wider clinical use and a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Some of the newer fluoroquinolones have an important role in the treatment of community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of the fluoroquinolones range from 3 -20 hours, allowing for once or twice daily dosing. You must have searched high and low for information on bronchitis (http://mccallk.createaforum.com/bronchitis-cures/chesty-cough-shortness-of-breath/), isn't it? That is the main reason we compiled this article for you to get that required matter!

Fourth Generation
The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while maintaining the gram-positive and gram-negative activity of the third-generation drugs. They also retain activity against Pseudomonas species comparable to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan).

Fluoroquinolones Advantages:
Ease of administration Daily or twice daily dosing  Excellent oral absorption Excellent tissue penetration  Prolonged half-lives Significant entry into phagocytic cells Efficacy Overall safety It is not always that we just turn on the computer, and there is a page about Chronic Bronchitis. We have written this article to let others know more about Chronic Bronchitis through our resources.

Because of their expanded antimicrobial spectrum, third-generation fluoroquinolones are useful in the treatment of community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, which are their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin. Now while reading about Chronic Bronchitis, don't you feel that you never knew so much existed about Chronic Bronchitis? So much matter you never knew existed.

Because of concern about hepatotoxicity, trovafloxacin therapy should be reserved for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), and the drug should be taken for no longer than 14 days. There are no boundaries on countries for one to access information about Bronchitis through the Internet. All one has to do is to surf, and then the required matter is availed!

First Generation
The first-generation agents include cinoxacin and nalidixic acid, which are the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were used primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing than the newer quinolones, and they are more susceptible to the development of bacterial resistance.

Side Effects
The fluoroquinolones as a class are generally well tolerated. Most adverse effects are mild in severity, self-limited, and rarely result in treatment discontinuation. However, they can have serious adverse effects.

All of the fluoroquinolones are effective in treating urinary tract infections caused by susceptible organisms. They are the first-line treatment of acute uncomplicated cystitis in patients who cannot tolerate sulfonamides or TMP, who live in geographic areas with known resistance > 10% to 20% to TMP-SMX, or who have risk factors for such resistance.

Fluoroquinolones Disadvantages:
Tendonitis or tendon rupture  Multiple drug interactions Not used in children Newer quinolones produce additional toxicities to the heart that were not found with the older agents Writing about Bronchitis is an interesting writing assignment. There is no end to it, as there is so much to write about it!  ;)

Classification of Fluoroquinolones
As a group, the fluoroquinolones have excellent in vitro activity against a wide range of both gram-positive and gram-negative bacteria. The newest fluoroquinolones have enhanced activity against gram-positive bacteria with only a minimal decrease in activity against gram-negative bacteria. Their expanded gram-positive activity is especially important because it includes significant activity against Streptococcus pneumoniae. Keep your mind open to anything when reading about Chronic Bronchitis. Opinions may differ, but it is the base of Chronic Bronchitis that is important.

Chronic bronchitis refers to inflammation and often infection of the bronchia, manifested by persistent, sputum-producing cough. Patients are diagnosed with chronic bronchitis if they experience sputum expectoration for more than three months of the year over a period of two years in a row, in the absence of other respiratory or cardio-vascular problems that can also generate recidivating cough. Chronic bronchitis usually occurs on the premises of weakened natural defenses of the respiratory tract (cilia barriers), triggered by infection with viral or bacterial organisms, or prolonged exposure to cigarette smoke, chemicals, industrial pollutants and other irritants. Most cases of chronic bronchitis occur as a result of interaction between these factors.

People with chronic bronchitis are usually prescribed combination treatments that include prophylactic antibiotics, corticosteroids, cough suppressants, expectorants (medications that have the opposite effects of suppressants) and chest physiotherapy. However, doctors don't recommend ongoing treatments with expectorants. Prolonged chest physiotherapy and postural drainage should also be avoided. Instead, cough-suppressing medications such as codeine or dextromethorphan can be prescribed in short courses for relieving persistent cough and obstruction of the airways. If there is the slightest possibility of you not getting to understand the matter that is written here on Bronchitis Treatment, we have some advice to be given. Use a dictionary!

Is important to note that there is no specific cure for chronic bronchitis. The treatment of chronic bronchitis varies from a patient to another, according to the intensity, the duration and the stage of the disease. The recurrent character of chronic bronchitis renders most medical treatments ineffective in completely overcoming the disease. Thus, the treatment of chronic bronchitis is primarily aimed at providing temporary symptomatic relief and preventing the occurrence of further complications. This article serves as a representative for the meaning of Chronic Bronchitis Treatment in the library of knowledge. Let it represent knowledge well.

The process of diagnosing chronic bronchitis, doctors usually account for two major aspects: the recurrence of the symptoms generated by the disease and conclusive evidence of patients' exposure to airborne irritants. Patients with chronic bronchitis may experience the following symptoms: sputum-producing cough (yellowish aspect of the phlegm and expectoration of blood are indicators for bacterial infections), chest pain and discomfort that intensify with deep breaths, wheezing, pronounced shortness of breath and accelerated breathing. Along with hypoventilation, cyanosis usually points to spreading of the disease at the level of the lungs. In the absence of an appropriate medical treatment, people with chronic bronchitis are very exposed to the development of serious complications such as emphysema and pneumonia.